Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease

Table 1 Demographic characteristics, transplant population, and study cohort n (%)

	Patients transplanted for PSC (n = 121)	Study cohort (n = 47)
Sex, recipients; male/female	88/33 (72.7/27.3)	31/16 (66/34)
Median age, recipient, yr (range)	36 (12-64)	36 (12-60)
Median age, donor, yr (range)	34 (2-66)	37 (10-61)
Median follow-up, mos (range)	87 (0-249)	116 (60-249)
MELD score at time of OLT, median (range)	15 (6-34)	15 (8-32)
Overlap syndrome AIH/PSC pre-OLT	20 (16.5)	5 (10.6)
Graft configuration: whole/reduced	116/5 (95.9/4.1)	47/0 (100/0)
Cholangiocarcinoma in liver explant	8 (6.6)	0 (0)
Cold ischemia median time, min (range)	300 (125-637)	319 (175-637)
Type of anastomosis: End-to-end/Roux-en-Y	31/90 (25.6/74.4)	7/40 (14.9/85.1)
Tacrolimus-based primary immunosuppressive regimen	92 (76.0)	32 (68.1)
Cyclosporine-based primary immunosuppressive regimen	29 (24.0)	15 (31.9)
IBD pre-OLT	76 (62.8)	29 (61.7)
UC	75 (98.7)	29 (100)
CD	1 (1.3)	0 (0)
Indeterminate colitis	0 (0)	0 (0)
Mild course of IBD pre-OLT	62 (81.6)	29 (100)
Active course of IBD pre-OLT	14 (18.4)	0 (0)
Colectomy pre-OLT	4 (3.3)	-
Liver retransplantation, total	15 (12.4)	7 (14.9)
Liver retransplantation, for rPSC	8 (6.6)	6 (12.8)

PSC: Primary sclerosing cholangitis; OLT: Orthotopic liver transplantation; AIH: Autoimmune hepatitis; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn´s disease; rPSC: Recurrent PSC.